With two recent studies demonstrating that TRP metabolism via TDO represents an alternative route to IDO1 activity employed by tumors (3, 34), there is an interest in pharmacological targeting of TDO for cancer immunotherapy. This evidence concerns the gene IDO1 and cancer.